
366: Viking’s obesity flop, ‘pharma to table’ drug sales
The Readout Loud
00:00
Challenges in Oral Weight Loss Treatments
This chapter examines Viking's oral weight loss drug and its market positioning against established injectable GLP-1 treatments. It highlights issues like high discontinuation rates, competitive dynamics, and executive compensation concerns in the biotech industry.
Transcript
Play full episode


